Antibiotic treatment of atherosclerotic cardiovascular disease

Circulation

Volumn 107, Issue 9, 2003, Pages 1228-1230

  Grayston, J Thomas ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotics; Atherosclerosis; Chlamydia pneumoniae; Clinical trials; Editorials

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DOXYCYCLINE; GATIFLOXACIN; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIALS; CORONARY DISEASE; HUMANS;

EID: 0037432302     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000056032.56396.89     Document Type: Editorial

References (15)

1. Zahn R, Schneider S, Frilling B, et al. Antibiotic therapy after acute myocardial infarction: A prospective randomized study. Circulation. 2003;107:1253-1259.
2. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
3. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS Study. Eur Heart J. 1999;20:121-127.
4. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000; 102: 1755-1760.
5. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation. 2002;105:1555-1560.
6. Leowattana W, Bhuripanyo K, Singhaviranon L, et al. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai. 2001;84 (Suppl 3):S669-S675.
7. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002;106:1219-1223.
8. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001;34:606-610.
9. Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg. 2001;88:1066-1072.
10. Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin Treatment Prevents Progression of Peripheral Arterial Occlusive Disease in C. pneumoniae Seropositive Men. Circulation. 2002;105:2646-2652.
11. Sander D, Winbeck K, Klingelhofer J, et al. Reduced progression of early Carotid Atherosclerosis after antibiotic treatment and C. pneumoniae seropositivity. Circulation. 2002;106:2428-2433.
12. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomized, double-blind, placebo-controlled trial. Lancet. 2001;357:2085-2089.
13. Grayston JT, Jackson LA, Kennedy WJ, et al. Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues. Am Heart J. 1999;138:S545-S549.
14. Grayston JT. Antibiotic treatment of C. pneumoniae for secondary prevention of cardiovascular events. Circulation. 1998;97:1669-1670.
15. Grayston JT. What is needed to prove that Chlamydia pneumoniae does, or does not, play an etiologic role in atherosclerosis. J Infect Dis. 2000;181 (Suppl 3):S585-S586.